- Home
- Solutions
- By Diseases
- Congenital Ophthalmic Diseases
- Cornea Plana
Cornea Plana (CP) represents a formidable challenge in ophthalmic genetics, typified by a markedly flattened cornea. As a research service provider, Protheragen is dedicated to advancing the science of vision health through our therapeutics development services, which encompass target identification, drug discovery, and preclinical research.
Cornea Plana (CP) is a rare genetic ocular disorder characterized by the flattening of the corneal curvature, leading to hypermetropia and a hazy corneal limbus. This condition significantly impacts vision and quality of life, necessitating specialized therapeutic interventions. The disorder presents in two forms: a milder autosomal dominant type I and a more severe autosomal recessive type II. Understanding the genetic basis of CP is crucial for developing targeted diagnostics and therapies.
Fig.1 Features in autosomal recessive cornea plana. (Khan T. A., et al., 2023)
Innovative Gene Therapy Approaches
Gene therapy holds tremendous promise for reversing the genetic defects responsible for Cornea Plana. Strategies involve delivering functional copies of genes or modifying existing gene sequences via cutting-edge vector systems. Gene therapy’s potential to restore keratocan functionality could revolutionize therapeutic paradigms, though further research and clinical trials are necessary to overcome delivery and ethical challenges.
Protein Supplementation and Replacement Technologies
Owing to the structural deficiencies caused by faulty protein expression, protein supplementation therapies are gaining traction. By providing the cornea with essential structural proteins, these therapies aim to ameliorate physical deformities associated with Cornea Plana. The feasibility of such therapeutics is being enhanced by advances in biotechnology, allowing for the synthesis of biologically active proteins in laboratory settings.
Protheragen is at the forefront of developing therapeutics for Cornea Plana, leveraging our extensive experience in genetic research and ophthalmic therapeutics. Our services encompass the full spectrum of drug development, from target identification to preclinical studies.
Protheragen provides specialized target identification and validation services to help clients identify novel therapeutic targets for cornea plana and confirm their relevance to disease pathogenesis. Our services include genetic and molecular profiling of cornea plana tissues and cell models, focusing on key pathways involved in corneal development, extracellular matrix (ECM) regulation, and keratocyte function—including the KERA gene and associated proteoglycan signaling pathways. We use advanced techniques such as RNA sequencing, proteomics, and CRISPR-Cas9 gene editing to characterize gene expression patterns, protein interactions, and cellular phenotypes in cornea plana models, enabling clients to prioritize targets with high therapeutic potential.
Validation services include in vitro functional assays using primary corneal cells, induced pluripotent stem cell (iPSC)-derived corneal organoids, and 3D tissue models to confirm that targeting specific molecules or pathways modulates key disease phenotypes—such as corneal curvature, ECM deposition, or keratocyte function. For example, we can assess the impact of target modulation on corneal fibroblast matrix secretion, epithelial-stromal interactions, and biomechanical properties using techniques like atomic force microscopy and OCE. Protheragen's team of experts also provides bioinformatics analysis to integrate multi-omics data, identify disease-specific biomarkers, and validate target druggability, ensuring that clients focus their resources on the most promising therapeutic targets.
To support high-throughput drug screening and mechanistic studies, Protheragen develops and utilizes specialized in vitro models that recapitulate the key features of cornea plana. These models include 3D organotypic cultures, iPSC-derived "minicorneal" organoids, and ex vivo porcine corneal models—each optimized to mimic the structural, cellular, and biomechanical abnormalities of human cornea plana. Our 3D corneal models incorporate all relevant cell types (epithelial, stromal, endothelial, and nerve cells) and ECM components, enabling the evaluation of therapeutic candidates on cell-cell and cell-matrix interactions critical for corneal function.
Our in vitro screening services include high-throughput and high-content screening of small molecules, peptides, therapeutic proteins, and gene therapy vectors to identify candidates that modulate cornea plana phenotypes. We use specialized readouts such as corneal curvature measurement, ECM composition analysis, keratocyte viability and function, and lipid deposition assessment to evaluate candidate efficacy. Protheragen also offers custom assay development to address client-specific research questions, such as the impact of therapeutic candidates on corneal biomechanics or limbal integrity. These in vitro services provide a cost-effective, ethical alternative to early-stage animal testing, enabling clients to prioritize candidates before advancing to in vivo studies.
Protheragen develops and uses validated in vivo animal models of cornea plana to evaluate the efficacy, pharmacokinetics, and safety of therapeutic candidates in a physiological context. Our models are designed to recapitulate the genetic and phenotypic features of human cornea plana, including reduced corneal curvature, hyperopia, limbal haze, and early arcus lipoides. We utilize both genetically modified models (e.g., KERA knockout mice) and induced models (e.g., ex vivo porcine corneal reshaping models) to address different research needs, ensuring that results are translatable to human disease.
Efficacy testing services include detailed ophthalmic evaluations using state-of-the-art imaging and diagnostic tools, such as optical coherence tomography (OCT), corneal tomography, tonometry, pachymetry, and fundus photography. We assess key endpoints including changes in corneal curvature, refractive error, corneal opacity, limbal integrity, and keratocyte function, providing quantitative data on therapeutic efficacy. Protheragen also integrates pharmacokinetic (PK) and pharmacodynamic (PD) studies to evaluate drug absorption, distribution, metabolism, and excretion in ocular tissues—including cornea, aqueous humor, and sclera—ensuring that therapeutic candidates reach target tissues at effective concentrations.
To support regulatory compliance and IND submissions, Protheragen provides comprehensive preclinical safety and toxicology evaluation services for cornea plana therapeutic candidates. Our services adhere to GLP (Good Laboratory Practice) standards and include single and repeat-dose toxicity studies, local ocular toxicity assessments, and immunogenicity testing—all tailored to the unique properties of ocular therapeutics. We evaluate potential adverse effects such as corneal irritation, inflammation, edema, endothelial cell damage, and systemic toxicity, using validated endpoints and specialized imaging techniques like laser flare photometry for quantitative inflammation assessment.
For gene therapy and cell therapy candidates, we offer additional safety evaluations including vector biodistribution, insertional mutagenesis risk assessment, and immune response profiling. Our team of toxicologists and ophthalmic experts works closely with clients to design study protocols that address regulatory requirements, providing detailed reports and data summaries to support IND filings. Protheragen also offers dose-ranging studies to identify the optimal therapeutic dose that balances efficacy and safety, helping clients optimize their therapeutic candidates for clinical translation.
Protheragen provides specialized PK/PD analysis services to characterize the absorption, distribution, metabolism, and excretion of cornea plana therapeutic candidates, as well as their dose-response relationships. Our services include ocular tissue sampling (cornea, aqueous humor, vitreous, sclera) and bioanalytical testing using sensitive techniques such as LC-MS/MS, ELISA, and quantitative PCR to measure drug concentrations and target engagement. We evaluate PK parameters including Cmax (maximum concentration), Tmax (time to maximum concentration), half-life, and tissue distribution, providing insights into drug bioavailability and ocular retention.
PD analysis focuses on quantifying the relationship between drug exposure and therapeutic effect, using biomarkers such as corneal curvature, ECM protein expression, keratocyte function, and lipid deposition. We integrate PK/PD data to develop pharmacokinetic-pharmacodynamic models that predict therapeutic efficacy at different doses and administration routes, helping clients optimize drug formulation and dosing schedules. Protheragen's PK/PD services are critical for ensuring that therapeutic candidates deliver consistent, effective concentrations to target tissues while minimizing systemic exposure and toxicity.
The development of effective therapies for Cornea Plana requires a deep understanding of the genetic aspects of the disease. Protheragen offers comprehensive preclinical research services to evaluate the safety and efficacy of potential Cornea Plana therapeutics. Our state-of-the-art facilities and experienced team conduct rigorous in vitro and in vivo studies to ensure that our drug candidates meet the highest standards of safety and efficacy. If you are interested in our services, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.